🇺🇸 FDA
Patent

US 12018074

Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 12018074 (Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases) held by CHEMOMAB LTD. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHEMOMAB LTD.
Grant date
Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P